Park Ha Biological Technology Prices Follow-On Public Offering at $0.112
Park Ha Biological Technology announced the pricing of a best-efforts follow-on public offering of 21,875,000 units at an offering price of $0.112 per Unit. Each Unit consists of one Class A ordinary share of the Company, par value $0.00002 per share and one warrant to purchase one Class A Ordinary Share. Each Warrant will have an exercise price of $0.112 per Class A Ordinary Share and will be exercisable beginning on the issuance date and ending on the one-year anniversary of the issuance date. The Company expects to receive aggregate gross proceeds of $2.45M from the offering, before deducting placement agent commissions and other estimated expenses payable by the Company, excluding the exercise of any Warrant offered. The offering is expected to close on or about January 28, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for the expansion of directly operated stores in China, and the specific allocation of net proceeds to each market will be based on market conditions. D. Boral Capital is acting as the Sole Placement Agent for the offering.
Trade with 70% Backtested Accuracy
Analyst Views on BYAH
About BYAH
About the author

- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
- Significant Pre-Market Gains: Gelteq Limited (GELS) surged 46% to $1.43 in pre-market trading, indicating strong market reaction to its clinical trial progress, which may attract further investor interest in its future performance.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 20% to $1.77, while Upexi, Inc. (UPXI) increased by 10% to $0.99, reflecting an overall positive sentiment in the biotech sector that could bolster market confidence in related companies.
- Pre-Market Declines: Elicio Therapeutics, Inc. (ELTX) plummeted 62% to $5.79 in pre-market trading, showcasing market disappointment over its clinical trial results, which may lead investors to reassess its future outlook.
- Other Declining Stocks: 20/20 Biolabs, Inc. (AIDX) fell 18% to $0.79, highlighting the market's sensitivity to risks associated with biotech companies, potentially impacting overall investment sentiment in the industry.
- Offering Size: Park Ha Biological Technology Co. has entered into a securities purchase agreement to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Use of Proceeds: The net proceeds from this offering will be utilized for general corporate and working capital purposes, reflecting the company's strategic intent to expand operations and enhance market competitiveness.
- Closing Timeline: The offering is expected to close around June 15, 2026, subject to customary closing conditions, demonstrating the company's timing acumen and commitment to investors.
- Registration Statement: The securities are being offered under an effective F-3 registration statement, ensuring compliance and providing transparent disclosures to investors, thereby bolstering market confidence.
- Financing Agreement: Park Ha Biological Technology has entered into a securities purchase agreement with several investors to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, expecting gross proceeds of approximately $2 million, reflecting strong market confidence in its business.
- Clear Use of Funds: The proceeds from this offering will be utilized for general corporate and working capital purposes, indicating the company's strategic intent to expand its skincare brand 'Park Ha' and related services, aiming to enhance its competitive position in the market.
- Transparent Issuance Details: The securities are being offered under an effective F-3 registration statement, with the offering expected to close on June 15, 2026, complying with relevant U.S. securities laws, which enhances investor trust.
- Defined Market Positioning: Since its establishment in 2016, Park Ha has opened five directly operated stores and 22 franchisees in China, committed to providing cost-effective skincare solutions, thereby solidifying its position in the rapidly growing skincare market.

- Strategic Partnership: Park Ha Biological and Star Plus Action have formed a strategic partnership to combine their expertise in skincare, healthcare, celebrity IP, and AI to develop an integrated beauty and wellness ecosystem, aiming to enhance market competitiveness.
- AI Nutritionist Launch: The company has launched an AI Nutritionist as a pilot product and plans to expand the platform with AI-powered store managers and virtual skincare specialists, providing customer analysis, personalized product recommendations, and skin assessments to enhance customer experience.
- Stock Surge: Shares of Park Ha Biological Technology Co. (BYAH) soared more than 190% in pre-market trading on Friday after the partnership announcement, reflecting strong market reaction, with shares up nearly 170% ahead of the opening bell.
- Optimistic Market Sentiment: Retail sentiment on Stocktwits indicates extremely bullish views on Park Ha, with message volumes at very high levels, despite BYAH stock being down 87% year-to-date, suggesting strong expectations for future growth.
- Strategic Partnership Initiated: Park Ha Biological Technology has formed a strategic partnership with Star Plus Action to integrate resources across healthcare, skincare product development, celebrity IP management, and AI, aiming to drive digital transformation in the beauty and wellness sector.
- First Smart Product Launch: The collaboration has already introduced its first smart product, the AI Nutritionist, as a pilot, with plans to roll out a full-chain intelligent service system featuring AI store managers and skincare specialists to enhance service precision in the industry.
- Market Context Analysis: As China's beauty economy and health-conscious consumption trends evolve, demand is shifting from standalone skincare products to integrated solutions that combine skincare and health management, prompting Park Ha Biological to address challenges like product homogeneity and service precision through this partnership.
- Celebrity IP Collaboration: Star Plus Action focuses on IP creation and operation, leveraging partnerships with celebrities like Jay Chou and Liu Genghong to drive consumer engagement, while also offering AI services such as nutritionists and live stream hosts to enhance market competitiveness.









